Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Account Payables (2020 - 2025)

Foghorn Therapeutics has reported Change in Account Payables over the past 6 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $1.1 million for Q4 2025, up 215.57% from a year ago — trailing twelve months through Dec 2025 was $481000.0 (up 119.43% YoY), and the annual figure for FY2025 was $481000.0, up 119.43%.
  • Change in Account Payables for Q4 2025 was $1.1 million at Foghorn Therapeutics, up from -$110000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for FHTX hit a ceiling of $1.7 million in Q1 2023 and a floor of -$1.4 million in Q2 2022.
  • Median Change in Account Payables over the past 5 years was -$65500.0 (2021), compared with a mean of $30050.0.
  • Peak annual rise in Change in Account Payables hit 847.62% in 2022, while the deepest fall reached 390.1% in 2022.
  • Foghorn Therapeutics' Change in Account Payables stood at -$21000.0 in 2021, then soared by 847.62% to $157000.0 in 2022, then tumbled by 250.32% to -$236000.0 in 2023, then soared by 241.53% to $334000.0 in 2024, then skyrocketed by 215.57% to $1.1 million in 2025.
  • The last three reported values for Change in Account Payables were $1.1 million (Q4 2025), -$110000.0 (Q3 2025), and -$747000.0 (Q2 2025) per Business Quant data.